Short Takes: July 25, 2025

Welcome, Tailor Made Compounding! Our newest Silver-level Corporate Patron, Tailor Made Compounding is a 503A pharmacy specializing in sterile and non-sterile patient-specific therapies. Licensed in 46 states, NABP-accredited and LegitScript-certified, and with a newly expanded 40,000+ square-foot facility, Tailor Made “upholds the highest standards for quality, safety, and compliance—empowering healthcare providers with the ability to optimize the health of their patients.” 

Don’t forget to check out all our 2025 Corporate Patrons. They support you — you should support them!

Kudos to the Ohio Board of Pharmacy. Its July 17 guidance on compounding semaglutide and tirzepatide is clear and practical, aligning with FDA’s enforcement discretion timelines and providing detailed FAQs that address real-world scenarios faced by pharmacies and outsourcing facilities. The FAQs also clarify that while further compounding of GLP-1s is no longer allowed after the FDA-designated dates, pharmacies may continue to dispense previously compounded or purchased 503B-sourced inventory through the product’s labeled beyond-use date. 

A compounding advisory committee that sidelines compounders. While in principle, the FDA Pharmacy Compounding Advisory Committee is a fine idea, in practice, PCAC is a stacked deck. As Scott explains in this week’s Compounding Interests, “The people with the most relevant expertise are barred from participating in the most critical decisions.” PCAC needs structural reform, and the fix isn’t complicated—check out our Blueprint for a solution.